Term
|
Definition
|
|
Term
| Amitriptyline -> Nortriptyline |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Blocks NE and 5HT reuptake |
|
Definition
|
|
Term
Anticholinergic (sedation, visual, GI, stasis)
Anti-histamine
Alpha blockade (hypotension, sexual function) |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Narrow therapeutic index (2-6 times therapeutic level) |
|
Definition
|
|
Term
| Most serious side effect in TCA |
|
Definition
| Cardiac toxicity (palpitations, tachycardia) due to Increased NE in heart |
|
|
Term
| Reason for decreased TCA compliance |
|
Definition
| Sexual dysfunction and loss of libido |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Cheese effect (hypertensive crisis) |
|
|
Term
| Inhibit breakdown of 5HT and NE |
|
Definition
|
|
Term
|
Definition
|
|
Term
| MAOI drug interaction/ side effect |
|
Definition
| Excitability with meperidine due to increased serotonin |
|
|
Term
|
Definition
Degradation of
Epi
NE
5-HT
dopamine, tyramine |
|
|
Term
|
Definition
Breakdown of
Dopamine
Tyramine
Phenylethylamine (precursor to NE) |
|
|
Term
|
Definition
| Due to decreased MAO-A = Increased tyramine = Increased NE in circulation = hypertensive crisis (IC bleeding and organ damage) |
|
|
Term
|
Definition
|
|
Term
|
Definition
Orthostatic hypotension
Insomnia
Weight gain
Sexual dysfunction |
|
|
Term
|
Definition
Mainly used in OCD
*ON EXAM: Not a SSRI |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| 5HT Syndrome (SS): hypertensive crisis |
|
|
Term
|
Definition
Little or no effect on NE/dopamine reuptake
Little or no anticholinergic, antihistamine or alpha-1 effects |
|
|
Term
| MAO: Selective blockade of 5HT reuptake |
|
Definition
|
|
Term
|
Definition
SSRIs
SNRIs
Tertiary TCAs
MAOIs (with serotenergic agents)
MAOIs with meperidine |
|
|
Term
|
Definition
| Fluoxetine : Ensure 5 weeks washout (vs. 2 weeks for other SSRIs) |
|
|
Term
|
Definition
Once daily
Start low dose
Anxiety dose is 1/2 of depression dose |
|
|
Term
|
Definition
GI
Somnolence/insomnia
Sexual dysfunction
Agitation/nervousness |
|
|
Term
|
Definition
Hyponatraemia with diuretics
Carbamzepine, phenytoin
With other psychotropics |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Reduced anti-cholinergic, alpha-blocking and histamine effects than TCAs
(SNRI also used for anxiety) |
|
|
Term
|
Definition
| 25-37.5 mg/day increase by 25-37.5 mg q4-7 days (max 150 mg/day) |
|
|
Term
|
Definition
| 75 mg/day titrated up by 75 mg per week (max 375 mg/day) |
|
|
Term
|
Definition
Mixed serotonin norepinephrine effects
MAO: Presynaptic alpha 2-antagonist (increase central noradrenergic and serotonergic NTs) |
|
|
Term
|
Definition
| Increased appetite and weight gain (15-20lbs in 1 month) |
|
|
Term
|
Definition
| NDRI (NE DA reuptake inhibitor) : inhibits weakly uptake of DA, NE and 5HT |
|
|
Term
|
Definition
Start 75-150 mg/day
Target 150-300 mg/day
Max 400 mg/day (SR) and 450 mg/day (XL) |
|
|
Term
|
Definition
GI, seizure, sexual dysfunction
**Also used for smoking cessation |
|
|
Term
|
Definition
Misc.
highly sedative and priapism in males (major SE) |
|
|
Term
|
Definition
Misc.
Effect due to NMDA blockade |
|
|
Term
|
Definition
|
|
Term
| Continuation treatment phase |
|
Definition
|
|
Term
| Maintenance treatment phase |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Energy and cognitive responses |
|
|
Term
|
Definition
|
|
Term
| Comorbidities with neuropathy use: |
|
Definition
|
|
Term
| Comorbidities with smoking or obesity use: |
|
Definition
|
|
Term
| Comorbidities with anxiety use: |
|
Definition
|
|
Term
| Comorbidities with Insomnia use: |
|
Definition
Paroxetine
Mirtazapine
Trazodone |
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibit NE, Serotonin and DA uptake for mild and moderate depression ONLY |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Increase neuronal membrane fluidity and increase NE, dopamine and serotonin |
|
|
Term
|
Definition
| > 9.6 gm per dayas adjunctive therapy |
|
|
Term
|
Definition
| 0.5 mg daily as adjunctive therapy |
|
|
